Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TCG Lifesciences and Endo enter discovery alliance

This article was originally published in Scrip

Executive Summary

TCG Lifesciences, a research services and informatics company, is collaborating with Endo Pharmaceuticals to discover novel small-molecule drug candidates for the treatment of pain. The tie-up will focus on an integrated approach involving medicinal chemistry, biology and animal pharmacology capabilities of TCG's discovery research arm, Chembiotek. Endo will have full ownership of the compounds developed under the collaboration as well as exclusive global rights. It will also finance all subsequent drug development and commercialisation activities, provide research funding and make milestone payments to TCG. TCG is based in India and is part of The Chatterjee Group, an investment conglomerate headquartered in New York.

You may also be interested in...



Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

India Regulatory Diary: Marketers Co-Accountable For Lapses In Manufacturing Quality

New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.

Ex-Janssen India Chief To Lead PE-Controlled Bharat Serums

Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.

Topics

Related Companies

UsernamePublicRestriction

Register

SC006468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel